A review of erlotinib and its clinical use
PA Tang, MS Tsao, MJ Moore - Expert opinion on pharmacotherapy, 2006 - Taylor & Francis
Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth
factor receptor. Encouraging activity as a single agent and in combination with other …
factor receptor. Encouraging activity as a single agent and in combination with other …
A review of erlotinib–an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
R Iyer, A Bharthuar - Expert opinion on pharmacotherapy, 2010 - Taylor & Francis
Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
[HTML][HTML] Erlotinib (tarceva) for the treatment of non–small-cell lung cancer and pancreatic cancer
CM Rocha-Lima, LE Raez - Pharmacy and Therapeutics, 2009 - ncbi.nlm.nih.gov
Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the
epidermal growth factor receptor. Randomized, controlled clinical studies have …
epidermal growth factor receptor. Randomized, controlled clinical studies have …
Erlotinib: a new therapeutic approach for non-small cell lung cancer
P Bonomi - Expert opinion on investigational drugs, 2003 - Taylor & Francis
Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …
Erlotinib hydrochloride.
JD Minna, J Dowell - Nature Reviews. Drug Discovery, 2005 - europepmc.org
Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a
class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor …
class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor …
Erlotinib (Tarceva): an update on the clinical trial program
RS Herbst - Seminars in oncology, 2003 - Elsevier
Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
Erlotinib hydrochloride.
J Dowell, JD Minna, P Kirkpatrick - Nature Reviews Drug Discovery, 2005 - nature.com
Abstract Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer
J Smith - Clinical therapeutics, 2005 - Elsevier
BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
Erlotinib in cancer treatment
MA Bareschino, C Schettino, T Troiani, E Martinelli… - Annals of oncology, 2007 - Elsevier
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …